Specifically Targeted Antimicrobial Peptides, or STAMPs, are designed by first identifying targeting domains in bacterial genomes using genomic mining techniques. An antimicrobial peptide is then linked to the targeting domain allowing us to specifically direct the antimicrobial activity to a pathogen or group of pathogens of choice within a microbial community.
The platform technology allows the STAMP to effectively re-engineer the microbiota by selectively killing the targeted pathogen while sparing the remaining healthy microorganisms within the indigenous microflora. This targeted approach represents an enormous improvement over broad-spectrum antibiotics that indiscriminately kill both beneficial and pathogenic bacteria. Treatment with STAMPs results in biofilm communities that remain intact and “healthier” after treatment, and serve as a barrier to prevent reinfection.
STAMP platform proof-of-concept has been demonstrated with the lead STAMP advancing to Phase 2 clinical trials (under US IND).